Pfizer Inc. / Valneva SE

Lyme disease prevention (multivalent OspA vaccine)

476K US cases/yr · $800M Estimated annual US Lyme disease economic burden 2018 (USD MM, direct medical + indirect costs) · 30000 Annual US CDC-confirmed surveillance cases (2019)

Disease Overview

Lyme disease is the most common vector-borne illness in the United States, caused by Borrelia burgdorferi sensu lato spirochetes transmitted via Ixodes scapularis (deer tick) bites. The CDC estimates approximately 476,000 Americans are diagnosed and treated for Lyme disease each year (2010-2018 health insurance claims data), with surveillance-confirmed cases concentrated in 14 high-incidence states across the Northeast, Mid-Atlantic, and upper Midwest. Untreated infection can progress through erythema migrans rash, flu-like symptoms, arthritis, neurologic manifestations (Bell's palsy, meningitis, radiculopathy), and Lyme carditis. While early infection responds well to a 2-4 week course of doxycycline or amoxicillin, post-treatment Lyme disease syndrome (PTLDS) — chronic fatigue, cognitive impairment, joint pain — affects 10-20% of patients and remains poorly understood. Lyme disease incidence has expanded geographically and risen approximately 2-3-fold since the early 1990s due to climate change, suburban deer densities, and forest fragmentation. There is no licensed Lyme disease vaccine in the US since GlaxoSmithKline withdrew LYMErix (a single-OspA recombinant vaccine) from the market in 2002 amid declining sales and a class-action lawsuit alleging autoimmune adverse events (the suit was dropped without payment, but commercial confidence never recovered). VLA15 is the only Lyme disease vaccine candidate in active clinical development globally as of 2020.

Competitive Landscape

At deal date (April 2020), VLA15 was the only Lyme disease vaccine candidate in active clinical development globally — competition was effectively absent in the prophylactic vaccine category. The historical comparator was GlaxoSmithKline's LYMErix (recombinant OspA-1, FDA-approved December 1998 for ages 15-70), which was withdrawn February 2002 after declining sales and a class-action lawsuit (subsequently dropped without payment) alleging arthritis-related adverse events; LYMErix peaked at ~$40M in 2001. Adjacent prophylactic approaches at deal date included MassBiologics' anti-Borrelia mAb (lyme PrEP, Pfizer-partnered later in 2020), shionogi's preclinical mAb candidate, and tick repellent / acaricidal interventions (permethrin, DEET). Active immunization competitors did not exist beyond VLA15. Therapeutic Lyme alternatives — once infection occurs — remained generic antibiotics (doxycycline, amoxicillin, ceftriaxone for late disease) with no innovator development. Underlying epidemiologic and policy drivers: CDC reclassified Lyme as a national notifiable disease in 1991, the One Health approach increasingly addressed deer/tick reservoirs, and the rising geographic spread (now established in 14+ states with active surveillance) created a credible market for an effective prophylactic vaccine. Pfizer's manufacturing scale, vaccines commercial infrastructure (Prevnar, Trumenba) and ability to fund VALOR Phase 3 (~9,400 subjects) made it the natural partner for clinical-stage Valneva.